全身性干扰素-α治疗人嗜T淋巴细胞病毒I型相关脊髓病

Systemic interferon-alpha in the treatment of HTLV-I-associated myelopathy.

作者信息

Kuroda Y, Kurohara K, Fujiyama F, Takashima H, Endo C, Matsui M, Neshige R, Kakigi R

机构信息

Department of Internal Medicine, Saga Medical School, Japan.

出版信息

Acta Neurol Scand. 1992 Jul;86(1):82-6. doi: 10.1111/j.1600-0404.1992.tb08059.x.

DOI:10.1111/j.1600-0404.1992.tb08059.x

PMID:1519481

Abstract

Treatment with interferon-alpha (IFN-alpha) was undertaken in 16 patients with human T-lymphotropic virus type I-associated myelopathy (HAM). All patients had progressive spastic paraparesis before treatment. Twelve patients were enrolled in an open therapeutic trial with a dose of 3.0 x 10(6) IU/day of IFN-alpha and 4 in a randomized, double-blind, multidose (3.0 x 10(6), 1.0 x 10(6) or 0.3 x 10(6) IU/day) trial. IFN-alpha was injected intramuscularly for 28 days. Eight of 12 patients enrolled in an open trial and 2 patients receiving a dose of 3.0 x 10(6) IU/day of IFN-alpha in a randomized trial showed clinical improvements during and after the treatment. The results showed that, although not for all patients, systemic IFN-alpha with a dose of 3.0 x 10(6) IU/day is effective in the treatment of HAM.

摘要

对16例成人T淋巴细胞白血病病毒I型相关脊髓病（HAM）患者进行了α干扰素（IFN-α）治疗。所有患者在治疗前均有进行性痉挛性截瘫。12例患者参加了一项开放治疗试验，给予IFN-α剂量为3.0×10⁶IU/天，4例患者参加了随机、双盲、多剂量（3.0×10⁶、1.0×10⁶或0.3×10⁶IU/天）试验。IFN-α肌肉注射28天。在开放试验中入组的12例患者中有8例以及在随机试验中接受3.0×10⁶IU/天剂量IFN-α治疗的2例患者在治疗期间及治疗后显示出临床改善。结果表明，虽然并非对所有患者有效，但剂量为3.0×10⁶IU/天的全身性IFN-α对HAM治疗有效。